Derazantinib (DZB), a FGFR inhibitor, has displayed potential anti-angiogenic effects in biochemical assays. In this study, we used in vitro and in vivo assays to explore this activity. Proliferation of human umbilical vein endothelial cells, their pVEGFR expression and downstream signalling, and vascular permeability in mouse skin are dose-dependently supressed by DZB. Susceptibility-contrast MRI using ferumoxytol demonstrated a reduction in fractional blood volume in subcutaneous colorectal cancer xenografts treated with DZB for 48h. This anti-angiogenic effect may be a relevant component of the activity of DZB in tumours bearing FGFR aberrations and may facilitate clinical activity against other solid tumours.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords